Covidien’s Mallinckrodt To Buy CNS Therapeutics For $100M
This article was originally published in The Pink Sheet Daily
Covidien’s pharmaceutical arm Mallinckrodt has announced its plans to acquire St. Paul, MN-based CNS Therapeutics for $100 million. The acquisition will complement Mallinckrodt’s own generic pain therapeutic offerings. Mallinckrodt is on track to be spun out of Covidien in mid-2013.